GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica

William F Jiemy1, Anqi Zhang1, Wayel H Abdulahad2

  • 1Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

PubMed
Abstract

Insights

Polymyalgia rheumatica (PMR) involves expanded and activated monocytes. Macrophages in affected tissues produce key inflammatory cytokines like IL-6, suggesting they are crucial therapeutic targets for PMR.

Area of Science:

  • Immunology
  • Rheumatology

Background:

  • Limited understanding of polymyalgia rheumatica (PMR) immunopathology, with peripheral blood studies suggesting macrophages are key players.
  • Investigating the factors driving pro-inflammatory macrophage development and function in PMR.

Purpose of the Study:

  • To identify factors driving pro-inflammatory macrophage development in PMR.
  • To elucidate the functional role of macrophages in PMR immunopathology.

Main Methods:

  • Flow cytometry to analyze monocyte phenotypes in peripheral blood and bursal fluid.
  • Immunohistochemistry and immunofluorescence to characterize macrophages in affected tissues.
  • In vitro macrophage differentiation cultures to assess cytokine functions.

Main Results:

  • Increased and activated monocytes (CD14highCD16- and CD14highCD16+) observed in PMR patients.
  • Macrophages dominated immune infiltrates in PMR tissue, expressing abundant pro-inflammatory cytokines, notably IL-6.
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) were significantly elevated in PMR tissue, driving IL-6 production.

Conclusions:

  • The monocyte compartment is expanded and activated in PMR.
  • Macrophages in PMR-affected tissues are significant producers of pro-inflammatory cytokines like IL-6.
  • A cytokine network involving GM-CSF, M-CSF, and IFN-γ likely drives macrophage pro-inflammatory functions, identifying macrophages as potential therapeutic targets for PMR.